1. Search Result
Search Result
Results for "

Bone Resorption

" in MedChemExpress (MCE) Product Catalog:

81

Inhibitors & Agonists

18

Peptides

2

Inhibitory Antibodies

20

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10294

    SB-462795

    Cathepsin Metabolic Disease Cancer
    Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
    Relacatib
  • HY-N9331

    Cimicidanol-3-O-β-d-xyloside

    Others Metabolic Disease
    Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .
    Cimicifugoside H-1
  • HY-P2273

    CGRP Receptor Metabolic Disease
    Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .
    Calcitonin (human)
  • HY-B0657

    Clodronate

    Others Others Cancer
    Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density .
    Clodronic acid
  • HY-122082

    Others Inflammation/Immunology
    Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis .
    Methopterin
  • HY-111248

    Others Others
    ABD-295 is an antiresorptive agent, osteoclast inhibitor, and biphenylsulfide derivative. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo [1] .
    ABD-295
  • HY-P1288

    PKC fragment (530-558)

    PKC Others
    Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
    Protein Kinase C (530-558)
  • HY-122077

    Chloride Channel Metabolic Disease
    NS5818 is a potent chloride channel inhibitor. NS5818 inhibits acidification and bone resorption. NS5818 has the potential for the research of osteoporosis .
    NS5818
  • HY-122082R

    Others Inflammation/Immunology
    Methopterin (Standard) is the analytical standard of Methopterin. This product is intended for research and analytical applications. Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis .
    Methopterin (Standard)
  • HY-113403

    Endogenous Metabolite Others
    Pyridinoline, a fluorescent material, is a bone resorption biomarker. Pyridinoline also is a type crosslink of collagen .
    Pyridinoline
  • HY-B0657A
    Clodronic acid disodium salt
    2 Publications Verification

    Clodronate disodium salt

    Others Inflammation/Immunology Cancer
    Clodronic acid (Clodronate) disodium salt, a first-generation bisphosphonate, is orally active osteoclastic bone resorption inhibitor. Clodronic acid disodium salt can be used in high bone turnover states, Paget s disease and osteolytic bone metastases .
    Clodronic acid disodium salt
  • HY-P1418

    Thyroid Hormone Receptor Endocrinology
    DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 in ex vivo and in vivo assays of bone resorption .
    DPC-AJ1951
  • HY-P1418A

    Thyroid Hormone Receptor Endocrinology
    DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 TFA in ex vivo and in vivo assays of bone resorption .
    DPC-AJ1951 TFA
  • HY-162280

    PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk Cancer
    PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca 2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .
    PROTAC BTK Degrader-9
  • HY-110318
    VUF11207 fumarate
    2 Publications Verification

    CXCR Inflammation/Immunology Cancer
    VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
    VUF11207 fumarate
  • HY-114275

    Fungal Parasite Apoptosis Infection Cardiovascular Disease Cancer
    Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .
    Justicidin B
  • HY-N6084

    α-Lupulic acid

    COX GABA Receptor Apoptosis Cardiovascular Disease
    Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABAA receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties .
    Humulone
  • HY-P0322

    EMD 56574

    Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
    GRGDSPK
  • HY-103352

    L-235

    Cathepsin Metabolic Disease
    L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC50 of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (Ki=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (Ki=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .
    L-006235
  • HY-P0322A

    EMD 56574 TFA

    Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
    GRGDSPK TFA
  • HY-129337

    Antibiotic Fungal Apoptosis Infection Cancer
    Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .
    Reveromycin A
  • HY-135594

    Estrogen Receptor/ERR Metabolic Disease
    4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .
    4'-Raloxifene-β-D-glucopyranoside
  • HY-123370

    Proton Pump Metabolic Disease Cancer
    FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
    FR-167356
  • HY-149852

    Others Inflammation/Immunology
    Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC50 value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .
    Anti-osteoporosis agent-3
  • HY-126825

    Others Metabolic Disease
    NE21650 potently inhibits farnesyl diphosphate (FPP) synthase. NE21650 is a weak inhibitor of isopentenyl diphosphate (IPP) isomerase. NE21650 is a potent inhibitor of protein prenylation in osteoclasts and macrophages and bone resorption in vitro .
    NE21650
  • HY-168090

    p38 MAPK NF-κB RANKL/RANK Endocrinology
    Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .
    Anti-osteoporosis agent-11
  • HY-12398
    TEI-9647
    1 Publications Verification

    VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
    TEI-9647
  • HY-A0020
    Eldecalcitol
    2 Publications Verification

    ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3

    VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol
  • HY-A0020R

    VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (Standard) is the analytical standard of Eldecalcitol. This product is intended for research and analytical applications. Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol (Standard)
  • HY-B0119
    Risedronic acid sodium
    1 Publications Verification

    Risedronate sodium

    Parasite Others
    Risedronic acid (Risedronate) sodium is a bisphosphonate that inhibits osteoclast-mediated bone resorption.
    Risedronic acid sodium
  • HY-N0094
    Ipriflavone
    2 Publications Verification

    Others Metabolic Disease Cancer
    Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.
    Ipriflavone
  • HY-113230

    Endogenous Metabolite Metabolic Disease
    Galactosylhydroxylysine is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine is released during bone resorption and has been shown to be elevated in metabolic bone loss .
    Galactosylhydroxylysine
  • HY-113230B

    Endogenous Metabolite Metabolic Disease
    Galactosylhydroxylysine hydrochloride is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine hydrochloride is released during bone resorption and has been shown to be elevated in metabolic bone loss .
    Galactosylhydroxylysine hydrochloride
  • HY-B0148
    Risedronic acid
    1 Publications Verification

    Risedronate

    Parasite Cancer
    Risedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.
    Risedronic acid
  • HY-P0090
    Calcitonin (salmon)
    1 Publications Verification

    Salmon calcitonin

    CGRP Receptor Cancer
    Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
    Calcitonin (salmon)
  • HY-B0148S

    Isotope-Labeled Compounds Others
    Risedronic Acid-d4 is the deuterium labeled Risedronic acid. Risedronic acid (Risedronate) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption[1][2].
    Risedronic Acid-d4
  • HY-P0284

    MMP Inflammation/Immunology
    C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).
    C-telopeptide
  • HY-N5023

    Others Metabolic Disease
    Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption
    Veraguensin
  • HY-P0090A

    Salmon calcitonin acetate

    CGRP Receptor Cancer
    Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .
    Calcitonin (salmon) (acetate)
  • HY-N13219

    Others Metabolic Disease
    Angelica Extract is an angelica extract, and its components include: Ligustilide. Angelica Extract can effectively inhibit the differentiation of osteoclasts, regulate osteoclastogenesis and/or bone loss. Angelica Extract has the potential to be used in the study of various bone diseases caused by excessive bone resorption. .
    Angelica Extract
  • HY-108685

    Alendronic acid monosodium salt

    Others Metabolic Disease
    Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .
    Alendronate sodium
  • HY-122075

    Others Metabolic Disease
    FR 78844 is a potent and orally active bone resorption inhibitor. FR 78844 has the potential for the research of diabetes associated osteopenia .
    FR 78844
  • HY-P4684

    PTHrP (107–111)

    PTHR Inflammation/Immunology
    Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .
    Osteostatin
  • HY-N0094R

    Others Metabolic Disease Cancer
    Ipriflavone (Standard) is the analytical standard of Ipriflavone. This product is intended for research and analytical applications. Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.
    Ipriflavone (Standard)
  • HY-106431

    Olpadronate; OLP

    Others Metabolic Disease Cancer
    Olpadronic acid (Olpadronate) is an orally active amino-bisphosphonate and inhibits bone resorption. Olpadronic acid also prevents bone destruction and tumor growth in the skeletal prostate cancer mouse model. Olpadronic acid can be used for research of osteoporosis, malignancies and rheumatoid arthritis .
    Olpadronic acid
  • HY-148698

    VD/VDR Others
    2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
    2MD
  • HY-N10117

    RANKL/RANK Others
    2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
    2,3-Bis(3-indolylmethyl)indole
  • HY-17397
    Strontium Ranelate
    2 Publications Verification

    Distrontium renelate; S12911

    CaSR Metabolic Disease
    Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .
    Strontium Ranelate
  • HY-B0631
    Alendronic acid
    5 Publications Verification

    Others Cancer
    Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
    Alendronic acid
  • HY-N7646

    Others Others
    Curculigoside B, a phenolic glycoside isolated from Curculigo orchioides, enhances the osteoblast proliferation, decreases the area of bone resorption pit, osteoclastic formation and TRAP activity. Antiosteoporotic and antioxidative activities .
    Curculigoside B

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: